Basal Cell Carcinoma Therapy

Warm sunshine feels so good on the skin, but over your lifetime the cumulative effects of long-term sun exposure and other sources of ultraviolet light can lead to basal cell carcinoma (BCC). Nearly three million Americans are diagnosed with BCC each year—making it the most common type of all cancers. With the number of cases expected to grow, more people will undergo basal cell carcinoma treatment. Although it is the mildest form of skin cancer and rarely spreads to vital organs, rare aggressive forms of the disease can be deadly if not treated properly.

For years, traditional basal cell carcinoma treatment—including Mohs—has involved invasive cutting through healthy tissue, painful healing, lengthy recovery and unsightly scarring. Sensus Healthcare is changing all that with a non-surgical treatment option—the SRT-100™.

Now patients undergoing basal cell carcinoma treatment don’t have to worry about permanent disfigurement, nerve damage or injury to muscles.

 

The SRT-100™ delivers a precise, calibrated dose of Superficial Radiation Therapy (SRT) that only penetrates five millimeters below the skin’s surface. This gentle basal cell carcinoma treatment effectively destroys cancer cells without cutting, bleeding, stitching or scarring.

Performed right in the doctor’s office, basal cell carcinoma treatment with the SRT-100™ is painless. Patients usually undergo a series of treatments. The SRT-100™ delivers optimum results—a 95 plus percent cure rate for non-melanoma skin cancer. Best of all, patients don’t need reconstructive plastic surgery afterward.

The SRT-100™ can be used to remove basal cell carcinoma anywhere on the body. It works especially well on BCC located on the face, lower lip, rim of the ear, balding scalp, neck, hands, arms and legs.

Squamous Cell Carcinoma Therapy

Nothing is more beautiful than healthy skin. But over your lifetime the damaging effects of ultraviolet rays—from the sun, tanning beds and other sources—can lead to squamous cell carcinoma (SCC). With nearly 700,000 new cases diagnosed each year, effective squamous cell carcinoma treatment is more important than ever. Left untreated, the telltale signs of SCC—scaly red patches, open sores that crust or bleed, and unattractive growths—can become disfiguring, even deadly if it invades tissue below the skin’s surface and spreads to the lymph nodes or other parts of the body. Experts believe as many as 8,800 people in the United States may have died from SCC in 2012. With the number of cases expected to increase dramatically in the coming years, more people will need treatment.

For years, traditional squamous cell carcinoma treatment—including Mohs—has involved invasive incisions that cut through healthy tissue, painful healing, lengthy recovery and unsightly scarring. Sensus Healthcare is changing all that with a non-surgical treatment option—the SRT-100™.

Now patients undergoing squamous cell carcinoma treatment don’t have to worry about permanent disfigurement, nerve damage or injury to muscles.

The SRT-100™ delivers a precise, calibrated dose of Superficial Radiation Therapy (SRT) that only penetrates five millimeters below the skin’s surface. This gentle squamous cell carcinoma treatment effectively destroys cancer cells without cutting, bleeding, stitching or scarring.

Performed right in the doctor’s office, squamous cell carcinoma treatment with the SRT-100™ is painless. Patients usually undergo a series of treatments. The SRT-100™ delivers optimum results—a 95 plus percent cure rate for non-melanoma skin cancer. Best of all, patients don’t need reconstructive plastic surgery afterward.

The SRT-100™ can be used to remove squamous cell carcinoma anywhere on the body. It works especially well on SCC located on the face, lower lip, rim of the ear, balding scalp, neck, hands, arms and legs.

Keloid Treatment

For nearly 18 million people afflicted by these unsightly, sometimes painful, claw-like growths, keloid removal can be elusive. In fact, the majority—nearly seven million sufferers—don’t even know keloid removal is available and believe they have to go through life with this embarrassing condition. As a result, keloids don’t just scar the skin, they can scar a person’s confidence.

The SRT-100™ is giving countless keloid sufferers new hope and new confidence.

Keloids are actually chronic, non-malignant tumors that form at the site of skin trauma. Individuals who have undergone cardiac, orthopedic, obstetrics, gynecological or plastic surgery often form keloids. Acne and chickenpox scars, ear piercing, burns and other skin injuries can also trigger them. While many people think they simply have to live with keloids, Superficial Radiation Therapy is a highly effective keloid removal treatment and boasts a cure rate of 94 plus percent. This is especially good news for the nearly 18 million people whose ethnicity makes them genetically prone to keloids—including African Americans, Latinos and Asians. 

Now there’s a keloid removal treatment that really works.

In the past, keloid removal often involved several surgeries. Unfortunately, the keloids usually grew back at each new incision site. With surgical keloid removal, the non-malignant tumors recurred in up to 90 percent plus of cases. When surgical keloid removal is followed by Superficial Radiation Therapy, recurrence drops dramatically to as low as 10 percent—often zero percent in many cases.

The SRT-100™ delivers a precise, calibrated dose of Superficial Radiation Therapy that only goes skin deep. This low-dose of Superficial Radiation Therapy safely destroys the cells that form keloids—keeping the skin smooth as the incision heals. Performed right in the doctor’s office, each non-invasive treatment is painless. Patients usually undergo a series of treatments depending on the incision site.

The SRT-100™ has been approved by the U.S. Food and Drug Administration to treat keloids caused by surgery or injury. Whether you are a patient or physician, discover why its unrivaled efficacy in keloid removal and treatment has earned it the moniker “The Keloid Cure.”